Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current.

Displaying 201 - 250 of 386

	Date Sort ascending
CL_2020-46.pdf	2020-10-26	INFORMATION ONLY Changes to Apheresis Platelet Yield Testing Customer Letter 2020-46 (PDF)
CL_2020-45.pdf	2020-10-23	ACTION REQUIRED Notice of eProgesaOutage Nov 1-2, 2020 - Product and Service Impacts Customer Letter 2020-45 (PDF)
CL_2020-44.pdf	2020-10-06	ACTION REQUIRED Immunoglobulin (Ig) Inventory Update and Action for Hospitals Customer Letter 2020-44 (PDF) \| NEBMC Letter (PDF)
CL_2020-43.pdf	2020-10-01	INFORMATION ONLY Fibryga® Product Monograph Changes Customer Letter 2020-43 (PDF) \| Fibryga® Product Monograph changes (PDF)
CL_2020-42.pdf	2020-09-24	INFORMATION ONLY Compatibility Testing Interference Risk in Patients Being Treated with Sarclisa™ (Isatuximab) Customer Letter 2020-42 (PDF) \| CBS Letter Isatuximab (PDF)
CL_2020-41.pdf	2020-09-17	INFORMATION ONLY Adynovate® 3000 IU Available Customer Letter 2020-41 (PDF) \| 3000 IU Adynovate Customer Letter (PDF)
CL_2020-40.pdf	2020-09-01	INFORMATION ONLY Improving Red Blood Cell Utilization Customer Letter 2020-40 (PDF)
CL_2020-39.pdf	2020-09-01	INFORMATION ONLY Electronic Fillable Patient Requisition Forms Customer Letter 2020-39 (PDF)
CL_2020-38.pdf	2020-08-14	INFORMATION ONLY Obizur® Temporary Labelling Update Customer Letter 2020-38 (PDF) \| Customer Letter Obizur
CL_2020-37.pdf	2020-08-13	ACTION REQUIRED FEIBA 2500IU Shortage Customer Letter 2020-37 (PDF)
CL_2020-36.pdf	2020-07-28	INFORMATION ONLY Plasma Protein and Related Products Contract Extensions Customer Letter 2020-36 (PDF)
CL_2020-35.pdf	2020-07-22	INFORMATION ONLY Panzyga 10g Available Customer Letter 2020-35 (PDF)
CL_2020-34.pdf	2020-07-22	INFORMATION ONLY Privigen® 10g and 40g Sizes Available Customer Letter 2020-34 (PDF)
CL_2020-33.pdf	2020-07-14	ACTION REQUIRED Cutaquig®4g Inventory Customer Letter 2020-33 (PDF)
CL_2020-31.pdf	2020-07-09	INFORMATION ONLY Octaplasma™ Blood Group B Customer Letter 2020-31 (PDF)
CL_2020-32.pdf	2020-07-09	INFORMATION ONLY Takeda Canada Inc.Amalgamation Notification Customer Letter 2020-32 (PDF) \| CBS - Takeda Amalgamation
CL_2020-30.pdf	2020-06-29	INFORMATION ONLY GamaSTAN® Product Update Customer Letter 2020-30 (PDF) \| Gamastan (IG-C) Update Letter \| Product Profile GamaSTAN
CL_2020-28.pdf	2020-06-26	ACTION REQUIRED Provision of K Negative Red Blood Cells for Females 45 Years and Under Customer Letter 2020-28 (PDF)
CL_2020-29_0.pdf	2020-06-26	INFORMATION ONLY Bi-Weekly Inventory Update: Plasma Protein and Related Products Customer Letter 2020-29 (PDF)
CL_2020-27.pdf	2020-06-25	ACTION REQUIRED New Unique Pool Number for Exchange Transfusion Components For Hospital Customers in Manitoba Only Customer Letter 2020-27 (PDF)
CL_2020-26.pdf	2020-06-15	INFORMATION ONLY Move of Canadian Blood Services Operations, Calgary Customer Letter 2020-26 (PDF)
CL_2020-25.pdf	2020-06-12	INFORMATION ONLY Gammagard Liquid 30g Inventory Alert Customer Letter 2020-25 (PDF)
CL_2020-23.pdf	2020-06-11	INFORMATION ONLY CSL Behring - Safety Seal Information Customer Letter 2020-23 (PDF) \| CSL Behring - Safety Seal Information
CL_2020-24.pdf	2020-06-11	ACTION REQUIRED Convalescent Plasma Component Codes and Information Customer Letter 2020-24 (PDF)
CL_2020-22.pdf	2020-06-08	INFORMATION ONLY Updates to Héma-Québec Component Codes for Deglycerolized Components Customer Letter 2020-22 (PDF)
CL_2020-21.pdf	2020-05-28	INFORMATION ONLY Electronic Fillable Patient Requisition Forms Customer Letter 2020-21 (PDF)
CL_2020-20.pdf	2020-05-26	INFORMATION ONLY Known Interference Between Rebinyn® and Laboratory Assays used to Diagnose Coagulopathy Caused by COVID-19 Infection Customer Letter 2020-20 (PDF) \| REBINYN assay statement in COVID-19 patients
CL_2020-19.pdf	2020-05-19	INFORMATION ONLY Changes to Request Patient Designated Plasma Protein Products for Panhematin® Customer Letter 2020-19 (PDF) \| Sample Request for Patient Designated Plasma Protein Products
CL_2020-18.pdf	2020-05-01	INFORMATION ONLY COVID-19 Convalescent Plasma Production Customer Letter 2020-18 (PDF)
CL_2020_17.pdf	2020-04-28	INFORMATION ONLY Exterior Cleansing of Shipping Containers and Blood Bags Customer Letter 2020-17 (PDF) \| NAC IP+C Appendix A COVID \| NAC IP+C for Blood Return to Inventory
CL_2020-16.pdf	2020-04-23	INFORMATION ONLY Additional Infection Control Measures Customer Letter 2020-16 (PDF)
CL_2020-15.pdf	2020-04-15	INFORMATION ONLY Known Interference Between Hemlibra® and Laboratory Assays used to Diagnose Coagulopathy Caused by COVID-19 Infection Customer Letter 2020-15 (PDF) \| COVID 19 and Hemlibra interactions with labs to diagnose DIC
CL_2020-14_0.pdf	2020-04-08	ACTION REQUIRED Fibrinogen Concentrate – Educational Resources and Supply Customer Letter 2020-14 (PDF) \| CSL RiaSTAP Customer letter \| CSL Medical Information Request Form \| Fibryga Customer Letter
CL_2020-13.pdf	2020-04-06	INFORMATION ONLY Shipment of Patient Samples to Diagnostic Services Ontario and Nunavut (ONN) Laboratory Southern and Central Ontario Hospitals Only Customer Letter 2020-13 (PDF)
CL_2020-12.pdf	2020-03-16	INFORMATION ONLY Takeda’s Patient Support Program (OnePath) Customer Letter 2020-12 (PDF) \| Takeda Patient Letter
CL_2020-11_0.pdf	2020-03-11	INFORMATION ONLY COVID-19 Customer Letter 2020-11 (PDF)
CL_2020-10.pdf	2020-03-02	INFORMATION ONLY Update for HLA/HPA Results Printed on Apheresis Platelet End Label Customer Letter 2020-10 (PDF)
CL_2020-09.pdf	2020-02-28	INFORMATION ONLY Eloctate® Supply Constraint Customer Letter 2020-09 (PDF)
CL_2020-08.pdf	2020-02-24	INFORMATION ONLY Introduction of Jivi® Customer Letter 2020-08 (PDF) \| Jivi Product Profile \| Introducing Jivi HCP Letter \| Sample Request Patient Designated Plasma Protein Products
CL_2020-07.pdf	2020-02-20	INFORMATION ONLY WinRho® SDF Canadian Labelled Product - Labelling Error Customer Letter 2020-07 (PDF) \| Saol CBS WinRho SDF Customer Letter
CL_2020-06.pdf	2020-02-18	INFORMATION ONLY Immune Globulin Plan – Additional Information Customer Letter 2020-06 (PDF) \| Cutaquig product info ProCare (PDF) \| DCL for CSL IG Availability (PDF) \| Panzyga Customer Letter (PDF)
CL_2020-05.pdf	2020-02-11	INFORMATION ONLY Kovaltry® Infusion Set Change Customer Letter 2020-05 (PDF) \| Kovaltry Infusion Set Change
CL_2020-04.pdf	2020-02-07	INFORMATION ONLY Transfer of Routine Saskatchewan Prenatal ABO-Rh and Antibody Testing from Canadian Blood Services Vancouver to Saskatchewan Hospitals Customer Letter 2020-04 (PDF)
CL_2020-03.pdf	2020-01-31	INFORMATION ONLY Cinryze® Supply – Additional Information Customer Letter 2020-03 (PDF) \| CINRYZE Blood Bank Director Letter - January 2020
CL_2020-02.pdf	2020-01-27	INFORMATION ONLY Ottawa National Immunohematology Reference Laboratory (NIRL) Relocation to the Brampton Operations Site Customer Letter 2020-02 (PDF)
CL_2020-01.pdf	2020-01-20	INFORMATION ONLY HLA/HPA Results Printed on Apheresis Platelet End Label Customer Letter 2020-01 (PDF)
CL_2019-40.pdf	2019-12-20	INFORMATION ONLY 2019 Holiday Message and Inventory Update Customer Letter 2019-40 (PDF)
CL_2019-39.pdf	2019-12-18	ACTION REQUIRED Immune Globulin Plan Customer Letter 2019-39 (PDF)
CL_2019-38.pdf	2019-12-12	INFORMATION ONLY Variable Printed Information on Humate-P® Cartons Customer Letter 2019-38 (PDF) \| Humate-P Carton
CL_2019-37.pdf	2019-12-11	INFORMATION ONLY Deglycerolizing Red Blood Cells Originally Collected in Anticoagulants other than CPD/SAGM Customer Letter 2019-37 (PDF)